Risk-based Imaging Strategies to Improve Breast Cancer Surveillance Outcomes
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance Outcomes
批准号:
10268352
负责人:
Janie M Lee
金额:
$15.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-27 至 2022-05-31
关键词:
AccountingAgeBilateralBiopsyBreastBreast Cancer DetectionBreast Cancer Surveillance ConsortiumBreast Magnetic Resonance ImagingCancer DetectionCharacteristicsClinicalCommunity PracticeConsensusData SetDecision MakingDetectionDevelopmentDiagnosisDiffuseDigital Breast TomosynthesisDigital MammographyEarly DiagnosisEffectivenessEventFaceFailureGoalsGuidelinesHealth PersonnelHealth SurveysHigh Risk WomanImageImaging technologyIndividualLearningMagnetic Resonance ImagingMalignant NeoplasmsMammary Gland ParenchymaMammographyMastectomyModelingMultimodal ImagingNonmetastaticOutcomePerformancePhysiciansRecommendationRecording of previous eventsRecurrenceResidual stateRiskRisk EstimateRisk FactorsTestingTimeTranslatingTumor BiologyTumor SubtypeUnited StatesWomanWomen&aposs GroupWorkbasebreast cancer diagnosisbreast densitybreast imagingclinical careclinical practiceclinically actionablecomparative effectivenessdemographicsdesigndiscrete timehigh riskimaging modalityimprovedmalignant breast neoplasmmortalitymultimodalitynovelradiologistrisk prediction modelscreeningsurveillance imagingsurveillance strategytomosynthesistreatment choicetreatment guidelinestreatment strategytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project 3 Currently, 2.8 million women in the United States with a personal history of breast cancer (PHBC) face years of imaging surveillance. Breast imaging surveillance is aimed at the early detection of second breast cancer events, either local recurrence or new cancers in the other breast, with the goal of decreasing breast cancer mortality. Treatment strategies for primary breast cancers routinely take into account women's clinical and tumor characteristics. However, unlike treatment guidelines, current surveillance guidelines recommend annual mammography for all women with a PHBC regardless of risk. With new information about tumor biology and emerging imaging technologies (digital breast tomosynthesis and breast MRI), we can move toward risk-based surveillance decision making by women and their physicians. Although new imaging methods show promise for screening, their ability to improve early second breast cancer detection and longer-term outcomes is not yet established. The overall goal of this project is to facilitate a shift from a single strategy of annual mammography for all women to individualized, risk-based strategies, incorporating the full range of available imaging modalities and reliable estimates of a woman's risk of surveillance outcomes. We propose to integrate women's risk factors and tumor characteristics to produce risk estimates for important surveillance mammography outcomes: benefits (early detection of second invasive breast cancer), and failures (interval detection of second breast cancer after negative mammography). Early evidence suggests that women's risk factors, primary breast cancer characteristics, age at diagnosis, mode of detection, and treatment choices can be used to identify women at high risk of surveillance mammography failure who might benefit from alternative surveillance strategies (tomosynthesis alone or mammography and MRI). In addition, women at low risk of surveillance failure could minimize their risk of false alarms by receiving mammography or tomosynthesis alone. Our scientific premise is that tailored strategies will improve surveillance outcomes by reducing both surveillance failures and false alarms compared with guideline-recommended annual mammography alone. Our specific aims are:
Aim 1: Determine the benefits and harms of surveillance tomosynthesis compared with digital mammography among women with a PHBC.
Aim 2: Develop novel risk prediction models to identify and directly compare a woman's cumulative absolute risk of surveillance mammography outcomes.
This project will combine clinical and imaging risk factors to estimate risks of important surveillance benefits, failures, and false alarms, supporting a shift away from a "one size fits all" annual surveillance strategy, toward individualized, risk-based strategies for women with a PHBC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance Outcomes
-
批准号:9982827
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2020
-
负责人:Janie M Lee
-
依托单位:
Project 3
-
批准号:10411223
-
项目类别:
-
资助金额:$21.32万
-
财政年份:2011
-
负责人:Janie M Lee
-
依托单位:
Project 3
-
批准号:10705593
-
项目类别:
-
资助金额:$19.26万
-
财政年份:2011
-
负责人:Janie M Lee
-
依托单位:
Clinical and Economic Evaluation of Breast MRI for High-Risk Screening
-
批准号:7471042
-
项目类别:
-
资助金额:$14.11万
-
财政年份:2008
-
负责人:Janie M Lee
-
依托单位:
Clinical and Economic Evaluation of Breast MRI for High-Risk Screening
-
批准号:8072600
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2008
-
负责人:Janie M Lee
-
依托单位:
Clinical and Economic Evaluation of Breast MRI for High-Risk Screening
-
批准号:8257983
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2008
-
负责人:Janie M Lee
-
依托单位:
Clinical and Economic Evaluation of Breast MRI for High-Risk Screening
-
批准号:7840453
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2008
-
负责人:Janie M Lee
-
依托单位:
Clinical and Economic Evaluation of Breast MRI for High-Risk Screening
-
批准号:7627980
-
项目类别:
-
资助金额:$14.22万
-
财政年份:2008
-
负责人:Janie M Lee
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: